:2016-07-11 ¿ÀÀü 10:43:15
ÆÊÆ÷Æ® º¹¾à¾È³»¹® ³»¿ë Áß º¯°æ»çÇ×À» ¾Æ·¡¿Í °°ÀÌ ¾È³»ÇØ µå¸³´Ï´Ù. ÆÊÆ÷Æ® º¹¾à¾È³»¹®¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ °ü½É¿¡ °¨»çµå¸®¸ç, º¹¾àÁöµµ ¹× ȯÀÚ »ó´ã¾÷¹«¿¡ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
1. º¯°æÀÏ: 16. 7. 7. 2. º¯°æ ³»¿ë: ¹Ú½º ³» ¾àÇ°¼³¸íÀ» Ãß°¡ÇÔ. (º´Àû µµ¹Ú, Æø½Ä, ¼º¿å°úÇ×Áø µî) 3. º¯°æ »çÀ¯: Aripiprazole ¼ººÐ ¾àÇ°(¾Æºô¸®ÆÄÀÌÁ¤)ÀÇ ¡°¾ÈÀü¼º ¼ÇÑ¡± ¹ßÇ¥µÊ. 4. º¯°æ ¾àÇ°: Aripiprazole ¼ººÐÀÇ ¾àÇ° Àüü ÷ºÎÇÑ ÆÄÀÏÀÇ 31ÆäÀÌÁö µî Âü°í
¡Ø º» ³»¿ëÀÇ ¹«´ÜÀüÀç ¹× Àç¹èÆ÷¸¦ ±ÝÁöÇÏ¿À´Ï °ü·Ã»çÇ×Àº ¸ÞÀÏÁÖ¼Ò pharmport@naver.comÀ¸·Î ¹®Àǹٶø´Ï´Ù.
[Ãâó] FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada)
|